A meta-analysis of interaction between Epstein-Barr virus and HLA-DRB1∗1501 on risk of multiple sclerosis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Xiao, Di ^a   Ye, Xingguang ^a   Zhang, Na ^a   Ou, Meiling ^a   Guo, Congcong ^a   Zhang, Baohuan ^a   Liu, Yang ^a   Wang, Man ^a   Yang, Guang ^a,b   Jing, Chunxia ^a,b  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DRB1 ANTIGEN; HLA-DRB1*15:01 ANTIGEN;

EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; META ANALYSIS; MULTIPLE SCLEROSIS; PHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; VIROLOGY;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HLA-DRB1 CHAINS; HOST-PATHOGEN INTERACTIONS; HUMANS; MULTIPLE SCLEROSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84949640406     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18083     Document Type: Article

References (50)

1. Pender, M. P. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17, 351-67 (2011).
2. Pandit, L., Malli, C., D'Cunha, A., Shetty, R. & Singhal, B. Association of Epstein-Barr virus infection with multiple sclerosis in India. J Neurol Sci 325, 86-9 (2013).
3. Consortium, I.M.S.G. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214-9 (2011).
4. Hillert, J. Human leukocyte antigen studies in multiple sclerosis. Ann Neurol 36 Suppl, S15-7 (1994).
5. Schmidt, H., Williamson, D. & Ashley-Koch, A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 165, 1097-109 (2007).
6. Sundstrom, P., Nystrom, L., Jidell, E. & Hallmans, G. EBNA-1 reactivity and HLA DRB1∗1501 as statistically independent risk factors for multiple sclerosis: a case-control study. Mult Scler. 14, 1120-2 (2008).
7. Ascherio, A. et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083-8 (2001).
8. Levin, L. I. et al. Multiple sclerosis and Epstein-Barr virus. JAMA 289, 1533-6 (2003).
9. Sundstrom, P. et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62, 2277-82 (2004).
10. Levin, L. I. et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496-500 (2005).
11. Almohmeed, Y. H., Avenell, A., Aucott, L. & Vickers, M. A. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS One 8, e61110 (2013).
12. Klein, J. & Sato, A. The HLA system. First of two parts. N Engl J Med 343, 702-9 (2000).
13. Lang, H. L. et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3, 940-3 (2002).
14. Barcellos, L. F. et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Human Molecular Genetics 15, 2813-2824(12) (2006).
15. Li, Q. et al. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. Journal of Virology 71, 71-4657 (1997).
16. De Jager, P. L. et al. Integrating risk factors: HLA-DRB1∗1501 and Epstein-Barr virus in multiple sclerosis. Neurology 70, 1113-8 (2008).
17. Lünemann, J. D. Epstein-barr virus: environmental trigger of multiple sclerosis? Journal of Virology 81, 6777-6784. (2007).
18. Kruger, S., Schroers, R., Rooney, C. M., Gahn, B. & Chen, S. Y. Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 26, 212-21 (2003).
19. Pender, M. P. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 351, 978-81 (1998).
20. van der Mei, I. A. et al. Human leukocyte antigen-DR15, low infant sibling exposure and multiple sclerosis: gene-environment interaction. Ann Neurol 67, 261-5 (2010).
21. Simon, K. C. et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1∗1501 on multiple sclerosis risk. Neurology 74, 1365-71 (2010).
22. P, S.m., M, N.m., K, R. & E, L. Antibodies to specific EBNA-1 domains and HLA DRB1∗1501 interact as risk factors for multiple sclerosis. Journal of Neuroimmunology 215, 102-107 (2009).
23. Waubant, E. et al. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler 19, 891-5 (2013).
24. Andersson, T., Alfredsson, L., Kallberg, H., Zdravkovic, S. & Ahlbom, A. Calculating measures of biological interaction. Eur J Epidemiol 20, 575-9 (2005).
25. Sharipo, A., Imreh, M., Leonchiks, A., Imreh, S. & Masucci, M. G. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med 4, 939-44 (1998).
26. Pender, M. P. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 24, 584-8 (2003).
27. Bray, P. F., Luka, J., Bray, P. F., Culp, K. W. & Schlight, J. P. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 42, 1798-804 (1992).
28. Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695-705 (1995).
29. Lunemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205, 1763-73 (2008).
30. Mangalam, A. K., Taneja, V. & David, C. S. HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. J Immunol 190, 513-8 (2013).
31. Siggs, O. M., Makaroff, L. E. & Liston, A. The why and how of thymocyte negative selection. Curr Opin Immunol 18, 175-83 (2006).
32. TJ., V. & MJ., K. A tutorial on interaction. Epidemiol. Methods 3, 33-72 (2014).
33. Waubant, E. et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76, 1989-95 (2011).
34. Pender, M. P. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun Rev 8, 563-8 (2009).
35. Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 196, 1749-53 (2007).
36. Munger, K. L. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Multiple Sclerosis Journal 17, 1185-1193 (2011).
37. Najafipoor, A., Roghanian, R., Zarkesh-Esfahani, S. H., Bouzari, M. & Etemadifar, M. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients. Cell Immunol 294, 9-12 (2015).
38. Hosang, G. M., Shiles, C., Tansey, K. E., McGuffin, P. & Uher, R. Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med 12, 7 (2014).
39. Little, J. et al. STrengthening the REporting of Genetic Association Studies (STREGA)-an extension of the STROBE statement. Genet Epidemiol 33, 581-98 (2009).
40. von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370, 1453-7 (2007).
41. Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 61, 288-99 (2007).
42. Sundqvist, E. et al. Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis. Neurology 79, 1363-8 (2012).
43. DeLorenze, G. N. et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 63, 839-44 (2006).
44. Yang, X. et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 32, 1826-32 (2009).
45. Rothman, K. J. The estimation of synergy or antagonism. American Journal of Epidemiology 103, 506-511 (1976).
46. Foraita, R. A conditional synergy index to assess biological interaction. Eur J Epidemiol 24, 485-94 (2009).
47. Dong, F. et al. The association of PTPN22 rs2476601 polymorphism and CTLA-4 rs231775 polymorphism with LADA risks: a systematic review and meta-analysis. Acta Diabetol 51, 691-703 (2014).
48. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-34 (1997).
49. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557-60 (2003).
50. Peng, Y. G. et al. Effects of salt substitutes on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr 100, 1448-54 (2014).